Ocular use of topical ketotifen fumarate 0.025% ophthalmic solution can protect allergic rhinoconjunctivitis patients against nasal signs and symptoms induced in a conjunctival allergen challenge (CAC).
The investigators, from Ophthalmic Research Associates in North Andover, Massachusetts, United States, report CAC nasal symptom scores in ketotifen-treated patients were significantly and clinically fewer than in those receiving placebo. Symptoms in 32 patients were measured at baseline, 10 minutes, 20 minutes and 30 minutes after drug or placebo administration.
The randomised, double-blind, parallel-group study used the CAC model. Participants were 18 years or older, willing to avoid disallowed medications, had a history of rhinoconjunctivitis and a positive skin test. There were 16 men and 16 women in the group. Mean age was 45 years. Nineteen patients received ketotifen and 13 received placebo.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!